-
Kenya's economy faces climate change risks: World Bank
-
'For sure': Macron to preach stronger Europe vision at G7 swansong
-
Crude prices plunge, stocks surge on US-Iran peace deal
-
Starbucks Korea to shutter outlets for history lessons after 'Tank Day' fiasco
-
Courts cracking down on error-strewn AI-assisted legal briefs
-
Bitter communion: Cuban priests ordered to ration mass wafers
-
In crisis-hit Cuba, World Cup offers brief respite
-
UK intercepts Russian shadow fleet vessel in Channel
-
London, Tokyo agree $24-bn investment deal
-
Indonesian economy comes up for air but struggles to win back investors
-
Trump says US-Iran deal to be signed Sunday, Hormuz to open after
-
Between Trump and a hard place: Fed chair Warsh to lead first rate meeting
-
High-school drop out to big time crime boss, Venezuela's 'Nino Guerrero'
-
US-Iran deal could be finalised soon, mediator Pakistan says
-
Thousands gather in Thai capital to mourn late princess
-
US says downed multiple Iran drones as both insist deal closer
-
SpaceX: Five key moments, from first launch to Starship megarocket
-
US clears Paramount's $111 bn Warner Bros. takeover
-
Iran and US say deal closer than ever
-
Cuba opens more sectors to private business
-
World Cup struggles to ignite US excitement
-
US appellate court upholds Sam Bankman-Fried criminal sentence
-
France bids farewell to girl, 11, whose killing sparked outrage
-
Wall Street wobbles as SpaceX shares launch, oil slides on Mideast deal hopes
-
SpaceX lifts off in record Wall Street debut
-
US deportation flight carrying Iranians en route to C.African Republic
-
At a Libyan university once ravaged by war, students dream again
-
Kenya mourns schoolgirls killed in suspected dorm arson attack
-
Stocks rally, oil slides on Mideast deal hopes
-
'All of us of are migrants,' pope says in Canary Islands
-
Switzerland split on immigration vote: four perspectives
-
Thai princess dies aged 47 after three years in hospital
-
Science fiction? Musk's lofty SpaceX goals unrealistic, skeptics say
-
Asia stocks up, oil down on Mideast deal hopes
-
From cage fights to the White House, UFC marches into mainstream
-
Pope ends Spain visit with migrant meetings
-
Ex-Tottenham owner sells art collection in blockbuster auction
-
Antarctic Peninsula sees record high June temperatures
-
US stocks rally, oil prices fall as Trump calls off fresh Iran strikes
-
SpaceX to make historic IPO that could make Musk a trillionaire
-
El Nino is back, but its effects vary widely
-
First leather bag from T-Rex cells to be auctioned in Paris
-
Four times as many icebergs calved from Greenland glaciers: study
-
Stocks rebound, oil wavers as traders weigh Iran, rates outlook
-
Niger criminalises same-sex relations with jail terms
-
Smuggled dinosaur fossils return to Mongolia after two decades
-
Over 260 Nigerians fleeing xenophobic attacks in S. Africa return home
-
Pope condemns 'indifference' towards migrants on Canaries trip
-
Sweden withdraws controversial proposal to jail 13-year-olds
-
Economic pressures 'manageable': Indonesian deputy finance minister
Trump’s Crackdown: Lives/Risk
In a dramatic push to tackle the skyrocketing cost of prescription drugs in the United States, President Donald Trump has taken decisive action against the pharmaceutical industry. With the stroke of a pen, he signed an executive order designed to slash drug prices, promising relief for millions of Americans burdened by exorbitant healthcare costs. However, this bold move has sparked fierce debate, with critics warning that the consequences could be catastrophic—potentially costing millions of lives due to drug shortages and stifled innovation.
Trump’s Plan to Lower Drug Prices
The executive order, enacted on May 12, 2025, seeks to align U.S. drug prices with those in other developed nations, where medications often cost a fraction of what Americans pay. Trump has long criticized the pharmaceutical industry for what he calls unfair pricing practices, arguing that U.S. consumers have been overcharged for years. The order aims to reduce prices by 30% to 80%, targeting both brand-name and generic drugs. It relies on voluntary compliance from drug companies, with the threat of future regulations looming if they fail to cooperate. For many patients, this could mean significant savings on medications that currently drain their finances.
The Dark Side: Drug Shortages Loom
While the goal of affordability is laudable, the plan has raised red flags among healthcare experts and industry leaders. One major concern is the risk of drug shortages. The U.S. already faces periodic shortages of critical medications, such as those used in cancer treatments and epidurals. Forcing pharmaceutical companies to lower prices could make it unprofitable to produce certain drugs, particularly low-cost generics. If production slows or stops, hospitals and pharmacies could struggle to secure enough supply, leaving patients without access to life-saving treatments. The ripple effect could be devastating, especially for vulnerable populations like cancer patients and the elderly.
A Blow to Innovation
Beyond immediate supply issues, the executive order could deal a severe blow to pharmaceutical innovation. Developing new drugs is an expensive and risky endeavor, often costing billions of dollars and taking years of research. The U.S. market, with its higher drug prices, has long been a key source of revenue for this work. If that revenue shrinks, companies may cut back on research and development, slowing the creation of new treatments for diseases like Alzheimer’s, cancer, and rare genetic disorders. A healthcare economist recently cautioned that such a move could “delay breakthroughs that millions of patients are counting on,” trading short-term savings for long-term losses in medical progress.
Economic Fallout
The economic implications are equally troubling. The pharmaceutical industry employs thousands of Americans and drives significant investment in the U.S. economy. Lower prices could lead to job cuts and reduced funding for new projects. One major drug company has already hinted at rethinking its $50 billion investment in the U.S. if the order takes full effect. While consumers might save money at the pharmacy, the broader economy could suffer as a result.
The Case for Change
Despite these risks, supporters argue that action is overdue. Prescription drug prices in the U.S. are nearly three times higher than in other advanced countries, forcing many Americans to ration their medications or skip doses entirely. Lowering prices could save billions of dollars and improve access for those with chronic conditions like diabetes or heart disease. For these patients, Trump’s order represents a lifeline—a chance to afford the drugs they need to survive.
A High-Stakes Gamble
As the dust settles, the debate rages on. Will Trump’s crackdown on the pharmaceutical industry deliver on its promise of affordable healthcare, or will it unleash a cascade of unintended consequences? The order’s success hinges on cooperation from an industry reluctant to sacrifice profits, and its failure could leave patients paying the ultimate price. For now, the nation watches as this high-stakes gamble unfolds, with millions of lives in the balance.
Is that Israel's final blow?
Israel presses Tehran
Iran lifts Dollar, sinks Euro
Hormuz Shock Risk rising
Brazil's trade-war boom
Iran's revenge rewired
Cuba's golden Goose dies
Mexico after El Mencho falls
Nicaragua on the brink?
Cuba: The Regime's last Card
Strike fears rise over Iran